Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 4/20 | 0.44 |
| ▸ | NPY1R | P25929 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5446439 | 0.91 | CNR2 (0.47) | CNR2HTR3A | |
| SCHEMBL5344053 | 0.88 | SMN1; SMN2 (0.53) | CNR2TP53NPY1RHTR2AHTR7 | |
| SCHEMBL5457534 | 0.88 | HTR3A (0.46) | CNR2HTR3A | |
| SCHEMBL5453740 | 0.86 | HTR3A (0.51) | CNR2TP53HTR3ATHRBRXFP1 | |
| SCHEMBL5464700 | 0.84 | IDO1 (0.47) | CNR2TP53HTR3ANPY1RHTR2A | |
| SCHEMBL5445683 | 0.83 | CNR2 (0.47) | CNR2HTR3A | |
| SCHEMBL5463074 | 0.81 | CNR2 (0.52) | CNR2HTR3A | |
| SCHEMBL14463749 | 0.80 | CNR2 (0.48) | CNR2HTR3AHTR2AHTR7 | |
| SCHEMBL5446450 | 0.79 | HDAC1 (0.54) | CNR2TP53 | |
| SCHEMBL14410846 | 0.79 | SMN1; SMN2 (0.53) | CNR2HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | CNR2 106/4885TP53 3721/4885HTR3A 373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.